Dec 30, 2015
VEGF-A/VEGFR Inhibition Restores Hematopoietic Homeostasis in the Bone Marrow and Attenuates Tumor Growth
R. K. O'Donnell, B. Falcon, J. Hanson, W. E. Goldstein, C. Perruzzi, S. Rafii, W. C. Aird, L. E. Benjamin , Cancer Research , DOI: 10.1158/0008-5472.CAN-14-3023
Antiangiogenesis–based cancer therapies, specifically those targeting the VEGF-A/VEGFR2 pathway, have been approved for subsets of solid tumors. However, these therapies result in an increase in hematologic adverse events. We surmised that both the bone marrow vasculature and VEGF receptor–positive hematopoietic cells could be impacted by VEGF pathway–targeted therapies. We used...
Dec 21, 2015
The AMPK-related kinase SNARK regulates muscle mass and myocyte survival
S. J. Lessard, D. A. Rivas, K. So, H.-J. Koh, A. Lima Queiroz, M. F. Hirshman, R. A. Fielding, L. J. Goodyear , The Journal of Clinical Investigation , DOI: 10.1172/CJI79197
The maintenance of skeletal muscle mass is critical for sustaining health; however, the mechanisms responsible for muscle loss with aging and chronic diseases, such as diabetes and obesity, are poorly understood. We found that expression of a member of the AMPK-related kinase family, the SNF1-AMPK-related kinase (SNARK, also known as...
Dec 10, 2015
Tank binding kinase 1 is a centrosome-associated kinase necessary for microtubule dynamics and mitosis
S. Pillai, J. Nguyen, J. Johnson, E. Haura, D. Coppola, S. Chellappan , Nature Communications , DOI: 10.1038/ncomms10072
TANK Binding Kinase 1 (TBK1) is a non-canonical IκB kinase that contributes to KRAS-driven lung cancer. Here we report that TBK1 plays essential roles in mammalian cell division. Specifically, levels of active phospho-TBK1 increase during mitosis and localize to centrosomes, mitotic spindles and midbody, and selective inhibition or silencing of...
Nov 30, 2015
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014
P. A. Ascierto, M. Atkins, C. Bifulco, G. Botti, A. Cochran, M. Davies , S. Demaria, R. Dummer, S. Ferrone, S. Formenti, T. F. Gajewski, C. Garbe, S. Khleif, R. Kiessling, R. Lo, P. Lorigan, G. Mc Arthur, G. Masucci, I. Melero, M. Mihm, G. Palmieri, G. Parmiani, I. Puzanov, P. Romero, B. Schilling, B. Seliger, D. Stroncek, J. Taube, S. Tomei, H. M. Zarour, A. Testori, E. Wang, J. Galon, G. Ciliberto, N. Mozzillo, F. M. Marincola, M. Thurin , The Journal of Translational Medicine , DOI 10.1186/s12967-015-0736
The fourth “Melanoma Bridge Meeting” took place in Naples, December 3–6th, 2014. The four topics discussed at this meeting were: Molecular and Immunological Advances, Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers. Until recently systemic therapy for metastatic melanoma patients was ineffective, but recent advances in tumor biology...
Nov 28, 2015
MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma
N. Makise, T. Morikawa, T. Nakagawa, T. Ichimura, T. Kawai, H. Matsushita, K. Kakimi, H. Kume, Y. Homma, M. Fukayama , Human Pathology , DOI: http://dx.doi.org/10.1016/j.humpath.2015.11.007
The melanoma-associated antigen A (MAGE-A) family comprises cancer-testis antigens that represent promising prognostic biomarkers and immunotherapy targets in several cancer types. The aim of this study was to investigate the significance of MAGE-A expression in upper urinary tract urothelial carcinoma in relation to clinicopathological features, lymphocytic infiltration, and clinical outcome....